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Background: Numerous studies have indicated that some patient subpopulations do not respond to the antithrombotic
effects of aspirin. The objective of this study was to evaluate aspirin-induced inhibition of platelet cyclooxygenase (COX)
using a flow cytometric technique in long-term aspirin users after carotid endarterectomy (CEA) and controls with newly
diagnosed carotid stenosis not taking aspirin and to compare these results with platelet function analyzer measurements.
Methods: The study included 86 patients with a history of CEA on long-term aspirin therapy (100 mg daily) and 29
age-matched patients with newly diagnosed carotid artery stenosis not taking aspirin. Platelet-rich plasma diluted with
phosphate-buffered saline was incubated with arachidonic acid (ARA) at a final concentration of 80 mol/L. After
staining with phycoerythrin-labeled anti-P-selectin (CD62p) antibody, platelet CD62p-antigen expression was measured
on a flow cytometer.
Results: Flow cytometric measurement of ARA-induced platelet activation showed an inhibition of ARA-induced platelet
stimulation in all patients on aspirin therapy, whereas all but two controls (95%) showed expected platelet reactivity. In
contrast, results of the platelet function analyzer measurements were normal in 16% of aspirin-treated patients.
Conclusions: Flow cytometric measurement of CD62p expression on platelets after incubation with ARA proved to be a
practicable tool to monitor aspirin-induced inhibition of platelet COX. Results in patients on long-term low-dose aspirin
therapy show that the inability of aspirin to inhibit platelet COX for both symptomatic and asymptomatic patients with
high-grade internal carotid artery stenosis is a very rare event. So-called aspirin resistance detected quite frequently by
platelet function analyzer measurement is most likely from COX-independent mechanisms. (J Vasc Surg 2007;45:
1142-7.)Aspirin (acetylsalicylic acid) is the most widely used
antiplatelet drug for the primary and secondary prevention
of arterial thrombotic events. Aspirin reduces platelet activ-
ity by irreversibly acetylating cyclooxygenase (COX), thus
inhibiting the production of platelet-derived thromboxane
A2.
1-4 Aspirin therapy has been shown to reduce the risk of
arterial thrombotic events in all vascular beds,3,4 yet in
some patients, there is a lack of expected effects. This has
lead to the use of the term aspirin resistance.
Unfortunately, the term aspirin resistance has been
applied to describe several quite different entities. Some-
times it is used to describe the inability of aspirin to reduce
platelet production of thromboxane A2,
5 others use the
term for a clinical failure of the drug or the inability to
produce anticipated effects on in vivo (bleeding time) or in
vitro tests of platelet functions.3,6,7
Some important questions need to be addressed, how-
ever. Is aspirin capable of blocking platelet COX and thus
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1142ultimately the production of thromboxane A2 in long-term
aspirin users? And if yes, why do patients receiving sufficient
aspirin therapy experience ischemic events? Can these pa-
tients be identified and treated alternatively?
In platelets, arachidonic acid (ARA) is converted to
thromboxane A2 by a reaction catalyzed by the enzymes
COX and thromboxane synthetase.5 Therefore, incubation
with ARA leads to a COX-dependent activation of platelets
that is inhibited by aspirin. Measuring ARA-induced plate-
let aggregation has been used to evaluate the effect of
aspirin on platelets,8 mostly by aggregometry. However,
the method has limited reproducibility, is extremely labor
intensive, and is unavailable in most laboratories.6
The objective of this study was to evaluate aspirin-
induced inhibition of platelet COX using a flow cytometric
technique in long-term aspirin users after carotid endarter-
ectomy and in controls with newly diagnosed carotid ste-
nosis not taking aspirin. Recent studies have demonstrated
that patients have transient aspirin resistance during carotid
endarterectomy that lasts about 24 hours.9,10 Yet to our
knowledge, no investigations so far have addressed a possi-
ble long-term effect.
The present study used a simple flow cytometric
method to evaluate the activity of COX in platelets by
measuring the activation antigen CD62p (P-selectin) on
platelet surfaces after stimulation of platelets with ARA.
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analyzer, PFA-100 (Behring, Marburg, Germany), a device
frequently used to detect aspirin resistance.11
MATERIALS AND METHODS
Patients. The study initially included 100 patients. To
ensure accurate aspirin use, all patients were tested for
compliance. Patients were given a 4-week supply of aspirin
and asked to return within 4 weeks with the box and the
remaining pills. Then, the remaining tablets were counted.
Patients not having taken the amount of tablets  three
tablets for the follow-up period of 24 days (range, 21 to 27
days) were not estimated as sufficiently compliant.
The study evaluated all patients who had high grade
internal carotid artery (ICA) stenosis 70% according to
North American Symptomatic Carotid Endarterectomy
Trial12 criteria, who had undergone carotid endarterec-
tomy at least 3 months preceding inclusion into the study,
and who had no interventions during the last 3 months. All
patients had been taking low-dose aspirin therapy for at
least 3 months (Thromboass, Lannacher Heilmittel Ltd,
Lannach, Austria) before surgery, and all patients with
symptomatic carotid disease had been taking low-dose
aspirin therapy at least 1 month before their ischemic
neurologic event. Patients taking other antiplatelet medi-
cations or those receiving oral anticoagulation with vitamin
K antagonists or heparin were excluded.
An age-matched group of 29 patients with newly diag-
nosed carotid artery stenosis taking no antiplatelet or anti-
coagulatory medication served as controls. All patients had
a stenosis of 70% to 90%, indicating revascularization.
The study was approved by the local Ethics Committee.
Blood collection and routine laboratory analyses.
A cubital vein was punctured after application of a light
tourniquet. Immediately after venipuncture, the tourni-
quet was released. First, blood was collected into a 5 mL
K3-ethylenediaminetetraacetic acid standard vacuum tube
(Vacuette, Greiner Bio-One, Kremsmünster, Austria),
which was used to determine the complete blood count.
Another 5 mL of blood was drawn in a Vacuette tube
containing sodium citrate (3.2% trisodium citrate; Greiner
Bio-One) to be used for flow cytometric measurements.
Then, 5 ml blood was drawn in a tube containing 3.8%
trisodium citrate for analysis of closure-time on the PFA-
100. Finally, blood for routine blood chemistry analyses
was drawn in a serum tube containing standard gel. Blood
samples were used for platelet analysis 20 minutes after
venipuncture. Routine hematology and chemistry analyses
were performed 2 hours after venipuncture.
Platelet stimulation and staining of P-selectin
(CD62p). First, platelet-rich plasma (PRP) was prepared
by centrifuging the citrated blood samples for 15 minutes
at 100g. PRP was diluted 1:10 with phosphate-buffered
saline (PBS), and 20 L of the diluted PRP was mixed with
10 L of ARA (final ARA concentration 80 mol/L;
Diamed, Cressier sur Morat, Switzerland) and incubated
for 10 minutes in a waterbath at 37°C. Then, 10 L of
phycoerythrin (PE)-labeled anti-CD62p (P-selectin) anti-body (Beckmann-Coulter, Miami, Florida) or the corre-
sponding isotype control of the same manufacturer was
added and samples were incubated for another 20 minutes
at room temperature in the dark. The reaction was stopped
by adding 500 L cold PBS. To minimize in vitro artifacts,
fixation or washing procedures were omitted.
To determine ARA-independent platelet activation,
samples were also incubated with PBS instead of ARA.
Results of PBS-stimulated activation were subtracted from
ARA-stimulated results to yield the true ARA-induced ef-
fect. To prove platelet reactivity, samples were also incu-
bated with adenosine diphosphate (ADP; final ADP con-
centration, 2.5 mol/L) instead of ARA.
In analogy to establishing a reference range, a range was
defined encompassing 95% of a group of subjects without
aspirin therapy (29 control patients and 80 healthy volun-
teers). To categorize platelet reactivity to ARA, a subject
was considered reactive if ARA stimulation induced expres-
sion of CD62p within this range; that is, exceeded the 0.05
percentile of subjects without aspirin therapy (ie, 15%
CD62p-positive platelets).
Flow cytometric analyses. Prepared samples were an-
alyzed on a FACScan flow cytometer (Becton Dickinson,
San Jose, Calif). Instrument stability was monitored by
daily measurement of calibrations beads (Calibrite 3 Beads,
Becton Dickinson). Side scatter, forward scatter, and fluo-
rescence signals were measured using the instrument’s log-
arithmic amplification mode. Data were acquired applying
a forward scatter threshold excluding all events smaller than
platelets. A minimum of 10,000 platelets was collected per
sample. Platelets were defined based on their light scatter
properties in a forward-scatter/side-scatter dot-plot and
gated into a FL-2 (PE-channel) histogram, where P-
selectin (CD62p) expression on the platelet surface was
measured. The percentage of CD62p PE-positive events
was determined by setting a threshold according to the
isotype control.
PFA-100. The PFA-100 is a platelet function analyzer
that has been designed as an in vitro measure of primary
hemostasis at high shear rate, mimicking flow conditions in
the arteries. Shear stress–induced capillary closure time of
whole blood was measured using a collagen/epinephrin-
coated membrane (EPI cartridge) and a collagen/ADP-
coated membrane (ADP cartridge). The reference range
was defined according to the recommendations of the
manufacturer, which was validated before the method was
adopted into laboratory routine. Thus, an aspirin response
was defined using the normal range cutoff of 165 seconds
on the EPI cartridge. Patients with a collagen-epinephrine
closure time (CEPI-CT) of165 seconds were considered
aspirin responders.
Statistical analysis. Statistical calculations were per-
formed with Statistica 5.1 (Statsoft, Tulsa, Okla) for Win-
dows (Microsoft, Redmond, Wash). Data are reported as
medians (lower quartile, upper quartile). For results not
following a normal distribution, nonparametric methods
were used to statistically describe and compare groups. The
nonparametric Mann-Whitney U test was used to evaluate
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RESULTS
Of the 100 patients initially included and tested for
compliance, 14 patients were excluded from the further
study. Of the remaining 86 patients, 47 were men and 39
women, and their median age was 73 years (range, 67 to
80). In the 86 patients who underwent operations for
carotid stenosis, 47 were symptomatic and 39 were asymp-
tomatic. Patient demographics, risk factors, and medica-
tions are listed in Tables I and II. Comparisons of PFA 100
results and CD62 expression according to clinical stage are
listed in Table III.
The age-matched group of 29 patients with newly
Table II. Medication of patients receiving aspirin after







Antihypertensive therapy 67 (78) 22 (76)
Oral antidiabetic therapy 29 (34) 9 (31)
Insulin 1 (1) 1 (3)
Statins 58 (67) 18 (62)
Aspirin 86 (100) 0 (0)
Table III. Comparisons of PFA 100 results and CD62
expression according to clinical stage






PFA 100 (sec) 300 (221, 300) 300 (200.3, 300) .55
CD62 (%) 3.85 (3.05, 4.98) 4.53 (2.07, 6.54) .37
PFA, Platelet function analyzer.
*Data represent median and 25th and 75th percentile.
Table I. Distribution of patient risk factors






Hypertension 32 (82) 36 (76)
Diabetes mellitus 13 (33) 17 (36)
Smoking 12 (31) 17 (36)
Hypercholesterolemia 22 (56) 30 (64)
Renal insufficiency 3 (7) 3 (6)
COPD 5 (13) 7 (15)
Angina 15 (38) 19 (40)
PAOD 11 (28) 13 (28)
COPD, Chronic obstructive pulmonary disease; PAOD, peripheral arterial
occlusive disease.diagnosed carotid artery stenosis taking no antiplateletmedication consisted of 20 men and 9 women, with a
median age of 72 years (range, 64 to 76 years). Of these, 13
were symptomatic, and 16 presented with asymptomatic
high-grade carotid stenosis.
Reactivity to arachidonic acid stimulation. Patients
and their respective platelets were considered reactive (and
thus not demonstrating the anticipated aspirin effect) if the
ARA-induced expression of CD62p exceeded the 0.05
percentile of subjects without aspirin therapy (15%; 29
matched controls and 80 tested healthy volunteers without
aspirin therapy; data not shown).
Applying this threshold, none of the platelets of the 86
patients receiving aspirin therapy were reactive to stimula-
tion by ARA (Fig 1). Conversely, the platelets of 27 (93%)
of the 29 patient controls were reactive to ARA, and two
(7%) showed no reactivity. ADP incubation significantly
increased the proportion of CD62p-positive platelets in all
patients. There was no difference between aspirin-treated
patients and patients without aspirin therapy (79% [72% to
87%] vs 81% [76% to 85%]; P  .252); platelets of all
patients were reactive to ADP. Patients receiving aspirin
therapy showed a slightly lower number of CD62-positive
platelets after PBS incubation than control patients [8% (5%
to 13%) vs 11% (9% to 15%); P .017]. The two patients in
the control group with a lack of reactivity to ARA both
showed an elevated CEPI-CT (166 seconds and 228 sec-
onds, respectively). Thus, intake of a COX-inhibiting drug
Fig 1. Activation of platelets by arachidonic acid (ARA): all 86
patients receiving long-term low-dose aspirin medication (ASP)
showed inhibition of ARA-induced platelet activation (ie, 15%
CD62p-positive platelets), whereas two of 29 patient controls
without reported history of aspirin intake (PCON) demonstrated
cyclooxygenase inhibition. The threshold of 15% is marked by the
dashed line.could not be excluded.
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(PFA-100). Contrary to flow cytometric results, 14 (16%)
of the 86 patients receiving aspirin showed no effect of
aspirin and had a normal CEPI-CT (Fig 2). There was no
difference in sex, age, or other risk factors or distribution of
normal PFA-100 readings between symptomatic and
asymptomatic patients. Four (14%) of the 29 patient con-
trols showed an increased CEPI-CT.
DISCUSSION
Aspirin resistance has been defined in many different
ways, possibly reflecting the lack of consideration of the
underlying pathophysiologic mechanisms.5,8 Accordingly,
the reported prevalence of aspirin resistance ranges from
1% to 40%.13,14 High prevalence is generally reported
when clinical definitions of aspirin resistance are applied or
the PFA-100 platelet function analyzer is used.14-16 Thus, a
clinical outcome or a surrogate of over all platelet function
is depicted without addressing the underlying biochemical
mechanisms of thromboxane A2–induced, COX-depen-
dent platelet aggregation.
One of the possible mechanisms of aspirin resistance is
the inability of aspirin to inhibit platelet COX. As several
isoforms of COX exist, and aspirin in its low-dose formu-
lation is mostly COX-1 selective, expression of other iso-
forms by megacaryocytes have been linked to treatment
failure.17 This effect takes place in the presence of systemic
inflammation that occurs in embolic events causing tissue
Fig 2. PFA-100 collagen-epinephrine closure time (CEPI-CT):
14 of 86 patients showed a normal CEPI-CT despite long-term
low-dose aspirin medication (ASP). Four of 29 patient controls
without an apparent history of aspirin intake (PCON) had an
elevated CEPI-CT. The upper reference limit (165 seconds) is
marked by the dashed line.damage—as for instance in brain or myocardial infarction.In the present study, we used a flow cytometric method
to evaluate the activity of platelet COX by measuring
platelet activation after incubation with ARA. COX cata-
lyzes a major step in the pathway from ARA to thrombox-
ane A2, a potent stimulator of platelet aggregation. Expres-
sion of surface CD62p was measured as a sign of ARA-
induced platelet activation.
Although sample manipulations should be kept to a
minimum for platelet analysis18 and whole blood methods
have been used successfully,19 we decided to use PRP
because we detected in vitro lysis of red blood cells when
PBS-diluted citrated whole blood was incubated with ARA
(already at a final concentration of 125 mol/L, data not
shown). ADP derived from the hemolysate might stimulate
platelets in an aspirin-independent way; therefore, the use
of PRP was preferred.
The use of the present method to detect aspirin resis-
tance in patients after carotid endarterectomy under long-
term low-dose aspirin therapy resulted in markedly de-
creased reactivity to ARA in all 86 patients, indicating
suppressed COX activity. The strength of this current study
is that the measured aspirin effects were underlined by
controls with the same disease not using aspirin, and the
expected reactivity to ARA was demonstrated in these
patients. This finding is of interest because monotherapy
with aspirin remains a cornerstone in stroke prevention,
especially in light of recent studies.20,21 Also, it has been
suggested that point-of-care tests such as PFA-100 and the
Ultegra-RPFA system (Accumetrics, San Diego, Calif) may
be used for detecting aspirin resistance in patients after
stroke.11 Yet, discrepant results of these tests and light
transmission aggregometry were seen.
In this study, neither asymptomatic nor symptomatic
patients with high grade ICA stenosis, whose symptoms
were under aspirin therapy, were aspirin resistant as mea-
sured by flow cytometry. This finding could indicate that
stroke in these patients may not have been caused by aspirin
failure.
Although this contrasts with results obtained by
other methods for detecting aspirin resistance (or so-
called aspirin resistance) or definitions, it is in very good
agreement with recent studies in which only 0.8% of
patients had aspirin-resistance when ARA-induced plate-
let aggregation was measured.13 Also, a recent study
with 700 patients undergoing coronary catheterization
revealed ARA-induced platelet activation in 2% of pa-
tients.22 These data suggest that aspirin resistance de-
fined as unsuppressed platelet COX activity is a very rare
phenomenon.
When analyzing the same group of aspirin-treated pa-
tients with the PFA-100, we observed a normal CEPI-CT
in 14 (16%) of 86 of patients, which is in agreement with
results of other studies.12-14 These patients may be re-
garded as “aspirin resistant” as frequently defined in studies
applying the PFA-100. Interestingly, aspirin-treated pa-
tients with a normal CEPI-CT did not show a higher
number of ARA-induced activated platelets than those with
a prolonged CEPI-CT (3.6% [2.8% to 4.2%] vs 4.5% [2.8%
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patients with normal CEPI-CT found with the PFA-100 is
not due to a more sensitive detection of residual COX
activity but that the PFA-100 detects other effects of plate-
let activation that are based on factors other than residual
platelet COX activity. And indeed, thromboxane A2–
induced COX-dependent platelet aggregation is only one
of many catalytic pathways of platelet aggregation.
The present study has several limitations. First, the
clinical relevance of elevated PFA-100 CEPI-CT in pa-
tients regarding increased risk for ischemic events could
not be addressed owing to the cross-sectional design.
Second, the sample size was too small to demonstrate a
possible difference in platelet reactivity between symp-
tomatic and asymptomatic patients. Third, we could
demonstrate that ARA-induced expression of CD62p
was suppressed in all patients; however, this effect de-
scribes only the aspirin effect on one platelet receptor.
Overall assessments of platelet activity and reactivity,
such as platelet-leukocyte or platelet-monocyte aggre-
gates, may be better comparable with PFA-100 CEPI-CT
and clinically more relevant.
CONCLUSION
Flow cytometric measurement of CD62p expression
on platelets after incubation with ARA proved to be a
practical tool to monitor aspirin-induced inhibition of
platelet COX. The results of this study and previous stud-
ies13,22 do suggest that aspirin does exert its desired effects
on the target enzyme in platelets in almost all compliant
patients. However, COX is only one of many, albeit impor-
tant, catalytic enzymes in the process of platelet aggrega-
tion. It seems that what is described as aspirin resistance
today—ischemic events under aspirin therapy—may have
other underlyingmechanisms than the inability of aspirin to
block platelet COX. In light of these findings, it appears
that PFA-100 could be more appropriate in detecting
patients prone to form thrombus under adequate aspirin
therapy. However, the underlying mechanism and its clin-
ical relevance need to be investigated further in longitudi-
nal studies.
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The authors’ manuscript reflects an area of growing interest in
other specialties and should serve to stimulate research opportuni-
ties in vascular surgery. Articles relating to aspirin resistance have
been published in the stroke and cardiology literature, where an
increasing number of studies have shown an association between
the incidence of adverse thrombotic events and aspirin resistance.
The subject, however, has not been widely addressed in the vascu-
lar literature.
While important, the manuscript must be taken in context. As
noted by the authors, aspirin resistance is not yet clearly defined,
and can be characterized by laboratory measures or adverse clinical
events. Laboratory measures of platelet function can include in
vivo testing, such as bleeding time. Ex vivo tests include the
measurement of arachidonic acid metabolites, such as urinary
11-dehydro TXB2; measures of platelet-platelet interaction, such
as optical or impedance aggregometry; point of care cartridge
based analyzers, such as the PFA-100; and whole blood flow
cytometry, which measures activation dependent changes on the
platelet surface (such as CD62p, p-selectin; activated GPIIb/IIIa;
leukocyte platelet aggregates), activation dependent signaling, and
activation dependent release from platelets. Of concern, however,
the reported incidence of aspirin resistance is variable, even using
comparable techniques; resistance in studies employing aggregom-
etry has ranged from 0.4% to 9%, and using the PFA-100 from 9%
to 35%.1
Clinical studies have demonstrated a higher incidence of aspi-
rin resistance among patients with a prior history of transient
ischemic attack or stroke; high risk patients with a history of
coronary artery disease have increased odds of being aspirin resis-
tant.2 Mueller et al.3 followed 100 patients with intermittent
claudication, treated with 100mg of aspirin per day, for 18months
after balloon angioplasty. Only 40% of male patients showed the
expected effect of aspirin using in vitro platelet aggregation. All
reocclusions at the site of angioplasty occurred in this group.aha, Neb
etry, urinary 11-dehydro TXB2 levels, and the PFA-100 have been
used to assess platelet function. Interestingly, results from the
PFA-100 did not correlate with aggregometry and did not corre-
late with vascular events.1
The current study uses two techniques to assess laboratory
evidence of aspirin resistance in patients on chronic aspirin therapy
and illustrates the caution that must be exercised in interpreting
results. Measurement of arachidonic acid induced expression of
CD62p (P-selectin), using flow cytometry, demonstrates that all
patients receiving aspirin show an aspirin effect, while PFA-100
closure times indicate 16% of patients taking aspirin show no effect
of aspirin. The PFA-100 can be influenced by multiple variables,
including platelet count, platelet function, red blood cells, and von
Willebrand factor; and the outcome can be effected by variables,
such as von Willebrand factor, that are not influenced by aspirin.
None-the-less, the current study is a very nice introduction to the
concept of aspirin resistance and provides an example of its appli-
cation in vascular surgery. While the study demonstrates evidence
of laboratory resistance, it has failed to exclude patient noncom-
pliance as a source of “resistance” and has not correlated laboratory
resistance with clinical evidence of adverse events. The study also
demonstrates that laboratory measures can influence the extent
and character of laboratory defined resistance. Future studies could
randomize aspirin therapy and laboratory adjusted aspirin therapy,
based on identified resistance; verification of compliance and doc-
umentation of clinical outcomes should be incorporated.
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